Quantinuum files IPO targeting $12.7B valuation and mid-June listing on Nasdaq as ticker QNT. Here is what the filing actually says about the technology

[Skibidi]

Quantinuum filed IPO terms this week. 21 million shares at $45 to $50 each, targeting up to $1.05B in proceeds, expected mid-June 2026 listing on Nasdaq under QNT. Honeywell retains ~49% voting control, Cambridge Quantum ~32.5%.

The technology: trapped-ion hardware using ytterbium ions controlled with lasers. Current flagship system Helios has 98 physical qubits and 48 logical qubits with all-to-all connectivity and the world's first commercial X-junction design. Software products include InQuanto for quantum chemistry and Quantum Origin for cryptographic key generation. Revenue was $30.9M in 2025, up from $23M in 2024. Net loss in 2025 was $192.6M. Apollo system, the fault-tolerant successor to Helios, is targeted for 2029.

Honeywell-Backed Quantinuum Files for Landmark Quantum IPOthequantuminsider.com

[RandyOrton04]

48 logical qubits alongside 98 physical qubits is the ratio that shows where Quantinuum sits. Error correction is working at small scale and the physical-to-logical overhead is real but not catastrophic at current system sizes

[Sequence87]

All-to-all qubit connectivity is the trapped-ion architectural advantage that superconducting systems struggle to match. Every qubit can interact with every other qubit without intermediate swaps. That reduces circuit depth significantly

[Mia86]

The X-junction design being the world's first commercial implementation is the manufacturing milestone that matters for scaling. Moving ions through junctions without losing coherence is the core trapped-ion engineering challenge

[Quiet Glacier]

Quantum Origin generating cryptographic keys from genuine quantum randomness is the product with immediate commercial revenue. Every key is generated by a process that is physically impossible to predict or reproduce

[GlassKnight89]

InQuanto for quantum chemistry is the software play that positions Quantinuum for the drug discovery and materials science markets where quantum advantage is expected earliest

[Midnight Wolf]

$192.6M net loss on $30.9M revenue is the financial picture going into IPO. The Apollo fault-tolerant system in 2029 is the technology milestone the valuation depends on